应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01877 君实生物
休市中 09-05 16:08:27
34.500
+3.680
+11.94%
最高
35.100
最低
30.680
成交量
1,925万
今开
31.360
昨收
30.820
日振幅
14.34%
总市值
354.32亿
流通市值
89.70亿
总股本
10.27亿
成交额
6.41亿
换手率
7.40%
流通股本
2.60亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
君实生物(01877.HK)提名杨劲为独立非执行董事候选人
智通财经 · 11:49
君实生物(01877.HK)提名杨劲为独立非执行董事候选人
君实生物：第四届董事会独立董事杨悦辞任
每日经济新闻 · 10:36
君实生物：第四届董事会独立董事杨悦辞任
9月5日君实生物-U涨7.38%，汇添富中证精准医疗指数(LOF)C基金重仓该股
证券之星 · 08:28
9月5日君实生物-U涨7.38%，汇添富中证精准医疗指数(LOF)C基金重仓该股
君实生物-U涨7.38%，太平洋四日前给出“买入”评级，目标价51.12元
证券之星 · 08:28
君实生物-U涨7.38%，太平洋四日前给出“买入”评级，目标价51.12元
港股异动 | 君实生物(01877.HK)涨超10% JT118获得药物临床试验批准通知书 公司多项研究成果入选WCLC
智通财经 · 07:16
港股异动 | 君实生物(01877.HK)涨超10% JT118获得药物临床试验批准通知书 公司多项研究成果入选WCLC
A股创新药板块持续上扬，泽璟制药涨超15%，三生国健、海辰药业涨超11%，博瑞医药、昭衍新药涨超9%，长春高新、君实生物、药明康德跟涨。
智通财经 · 06:36
A股创新药板块持续上扬，泽璟制药涨超15%，三生国健、海辰药业涨超11%，博瑞医药、昭衍新药涨超9%，长春高新、君实生物、药明康德跟涨。
港股创新药概念股持续拉升泰凌医药涨超10%君实生物、康龙化成、石四药集团、中国生物制药均涨超5%。
智通财经 · 02:37
港股创新药概念股持续拉升泰凌医药涨超10%君实生物、康龙化成、石四药集团、中国生物制药均涨超5%。
君实生物股价跌5.02%，招商基金旗下1只基金重仓，持有1.58万股浮亏损失3.68万元
新浪财经 · 09-04 06:03
君实生物股价跌5.02%，招商基金旗下1只基金重仓，持有1.58万股浮亏损失3.68万元
君实生物盘中异动 大幅下挫5.04%报30.900港元
市场透视 · 09-04 02:54
君实生物盘中异动 大幅下挫5.04%报30.900港元
猴痘概念盘中拉升，透景生命涨5.23%
市场透视 · 09-04 01:42
猴痘概念盘中拉升，透景生命涨5.23%
每日卖空追踪 | 君实生物 09月03日卖空量成交4.46万股，卖空比例为0.62%
市场透视 · 09-03 08:30
每日卖空追踪 | 君实生物 09月03日卖空量成交4.46万股，卖空比例为0.62%
东富龙：恒瑞医药、百济神州、君实生物是公司重要的合作伙伴
市场资讯 · 09-03 08:19
东富龙：恒瑞医药、百济神州、君实生物是公司重要的合作伙伴
君实生物：第四届监事会第九次会议决议公告
证券日报 · 09-03 07:37
君实生物：第四届监事会第九次会议决议公告
君实生物激励方案发布 A+H双发力 董事长获800万份A股期权
财中社 · 09-03 02:20
君实生物激励方案发布 A+H双发力 董事长获800万份A股期权
君实生物(01877.HK)建议采纳2025年H股股票期权激励计划和2025年A股股票期权激励计划
智通财经 · 09-02
君实生物(01877.HK)建议采纳2025年H股股票期权激励计划和2025年A股股票期权激励计划
君实生物JT118注射液获得国家药监局临床试验批准通知
美股速递 · 09-02
君实生物JT118注射液获得国家药监局临床试验批准通知
君实生物(01877.HK)：JT118注射液获得药物临床试验批准通知书
智通财经 · 09-02
君实生物(01877.HK)：JT118注射液获得药物临床试验批准通知书
君实生物(688180.SH)拟授出2617.59万份股票期权 行权价为46.67元/份
智通财经 · 09-02
君实生物(688180.SH)拟授出2617.59万份股票期权 行权价为46.67元/份
君实生物(688180.SH)：JT118注射液用于预防猴痘病毒感染临床试验获批准
智通财经 · 09-02
君实生物(688180.SH)：JT118注射液用于预防猴痘病毒感染临床试验获批准
华安证券：给予君实生物买入评级
证券之星 · 09-01
华安证券：给予君实生物买入评级
加载更多
公司概况
公司名称：
君实生物
所属市场：
SEHK
上市日期：
--
主营业务：
上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。
发行价格：
--
{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":34.5,"timestamp":1757059707005,"preClose":30.82,"halted":0,"volume":19245000,"delay":0,"floatShares":260000000,"shares":1027000000,"eps":-1.4219576657700856,"marketStatus":"休市中","change":3.68,"latestTime":"09-05 16:08:27","open":31.36,"high":35.1,"low":30.68,"amount":641414710,"amplitude":0.143413,"askPrice":34.52,"askSize":2400,"bidPrice":34.5,"bidSize":2600,"shortable":3,"etf":0,"ttmEps":-1.367569972681558,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1757295000000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":30.82,"openAndCloseTimeList":[[1757035800000,1757044800000],[1757048400000,1757059200000]],"volumeRatio":2.1590761052627463,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":48,"timestamp":1757055600000,"preClose":44.7,"halted":0,"volume":25289300,"delay":0,"premium":"-34.29"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2565550358","title":"君实生物(01877.HK)提名杨劲为独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2565550358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565550358?lang=zh_cn&edition=full","pubTime":"2025-09-05 19:49","pubTimestamp":1757072993,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","BK0239","BK1515","688180","01877"],"gpt_icon":0},{"id":"2565554224","title":"君实生物：第四届董事会独立董事杨悦辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2565554224","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565554224?lang=zh_cn&edition=full","pubTime":"2025-09-05 18:36","pubTimestamp":1757068602,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月5日，君实生物公告，杨悦女士因其他工作安排，申请辞去公司第四届董事会独立董事及相关委员会委员职务。公司已提名杨劲先生为新的独立董事候选人，待股东大会审议通过后正式任命。同时，杨劲先生将接替杨悦女士担任薪酬与考核委员会委员，鲁琨女士将接替杨悦女士担任提名委员会委员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509053506249134.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509053506249134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2565855875","title":"9月5日君实生物-U涨7.38%，汇添富中证精准医疗指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2565855875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565855875?lang=zh_cn&edition=full","pubTime":"2025-09-05 16:28","pubTimestamp":1757060913,"startTime":"0","endTime":"0","summary":"证券之星消息，9月5日君实生物-U涨7.38%，收盘报48.0元，换手率3.3%，成交量25.29万手，成交额11.73亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为汇添富基金的汇添富中证精准医疗指数C。汇添富中证精准医疗指数C目前规模为3.77亿元，最新净值1.0434，较上一交易日下跌4.32%，近一年上涨67.27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500026664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK1583","01877","688180","BK0239"],"gpt_icon":0},{"id":"2565810553","title":"君实生物-U涨7.38%，太平洋四日前给出“买入”评级，目标价51.12元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565810553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565810553?lang=zh_cn&edition=full","pubTime":"2025-09-05 16:28","pubTimestamp":1757060903,"startTime":"0","endTime":"0","summary":"今日君实生物-U涨7.38%，收盘报48.0元。2025年9月1日，太平洋研究员周豫,戎晓婕发布了对君实生物的研报《收入同比增长49%，25H2关注PD-1/VEGF数据读出》，该研报对君实生物给出“买入”评级，认为其目标价为51.12元，现价距离目标价尚有6.50%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为71.63%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的韩世通。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500026660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180","601099"],"gpt_icon":0},{"id":"2565371245","title":"港股异动 | 君实生物(01877.HK)涨超10% JT118获得药物临床试验批准通知书 公司多项研究成果入选WCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2565371245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565371245?lang=zh_cn&edition=full","pubTime":"2025-09-05 15:16","pubTimestamp":1757056572,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01877","BK0239","BK1161","688180","BK1583","BK1515"],"gpt_icon":0},{"id":"2565684532","title":"A股创新药板块持续上扬，泽璟制药涨超15%，三生国健、海辰药业涨超11%，博瑞医药、昭衍新药涨超9%，长春高新、君实生物、药明康德跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2565684532","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565684532?lang=zh_cn&edition=full","pubTime":"2025-09-05 14:36","pubTimestamp":1757054168,"startTime":"0","endTime":"0","summary":"A股创新药板块持续上扬，泽璟制药涨超15%，三生国健、海辰药业涨超11%，博瑞医药、昭衍新药涨超9%，长春高新、君实生物、药明康德跟涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/09/05143652945282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0052750758.USD","159992","BK0239","688266","LU0320764599.SGD","LU1934453819.USD","LU2125910500.SGD","BK0075","399300","BK1574","688336","LU2488822045.USD","BK1583","LU2328871848.SGD","06978","603259","BK0188","688180","LU1997244956.HKD","BK0046","BK1141","LU1997245094.SGD","BK1161","688166","BK0057","BK1576","LU0456842615.SGD","LU0708995583.HKD","LU2045819591.USD","LU2495084118.USD","603127","LU1969619763.USD","06127","BK1515","159982","LU1808992512.USD","LU1046422090.SGD","LU1979443071.USD","BK0216","BK0028","LU1997245177.USD","01877","LU2242644610.SGD","000661","300584"],"gpt_icon":0},{"id":"2565538660","title":"港股创新药概念股持续拉升泰凌医药涨超10%君实生物、康龙化成、石四药集团、中国生物制药均涨超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2565538660","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565538660?lang=zh_cn&edition=full","pubTime":"2025-09-05 10:37","pubTimestamp":1757039823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YT58.USD","LU2460026573.USD","01877","BK1574","02005","IE00BZ08YR35.GBP","HSTECH","IE00BZ08YS42.EUR","BK1576","BK0216","01177","159992","07226","BK1161","BK1583","BK0239","01011","BK1589","BK1521","688180","BK1191","300759","YANG","06978","HSCEI","BK1515","03759","BK1141","BK4614"],"gpt_icon":0},{"id":"2564308818","title":"君实生物股价跌5.02%，招商基金旗下1只基金重仓，持有1.58万股浮亏损失3.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564308818","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564308818?lang=zh_cn&edition=full","pubTime":"2025-09-04 14:03","pubTimestamp":1756965780,"startTime":"0","endTime":"0","summary":"9月4日，君实生物跌5.02%，截至发稿，报44.04元/股，成交9.07亿元，换手率2.58%，总市值452.15亿元。从基金十大重仓股角度数据显示，招商基金旗下1只基金重仓君实生物。招商中证疫苗与生物技术ETF二季度减持4360股，持有股数1.58万股，占基金净值比例为3.03%，位居第七大重仓股。根据测算，今日浮亏损失约3.68万元。截至发稿，侯昊累计任职时间8年16天，现任基金资产总规模554.59亿元，任职期间最佳基金回报188.21%， 任职期间最差基金回报-58.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509041445529776fa7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509041445529776fa7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1515","01877","BK1161"],"gpt_icon":0},{"id":"2564358372","title":"君实生物盘中异动 大幅下挫5.04%报30.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564358372","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564358372?lang=zh_cn&edition=full","pubTime":"2025-09-04 10:54","pubTimestamp":1756954482,"startTime":"0","endTime":"0","summary":"2025年09月04日早盘10时54分，君实生物股票出现波动，股价大幅下挫5.04%。截至发稿，该股报30.900港元/股，成交量366.94万股，换手率1.41%，振幅8.30%。君实生物股票所在的生物技术行业中，整体跌幅为4.34%。该信息摘要如下：君实生物早盘涨超5%，截至发稿，涨4.84%，报32.48港元，成交额7916.24万港元。消息面上，近日，君实生物公布2025年中期业绩，营业收入约11.68亿元，同比增长48.64%；归属于上市公司股东的净亏损约4.13亿元，同比收窄约36%；基本每股亏损0.42元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904105442a4b2e301&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904105442a4b2e301&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1161","BK1515","BK1583"],"gpt_icon":0},{"id":"2564372398","title":"猴痘概念盘中拉升，透景生命涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564372398","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564372398?lang=zh_cn&edition=full","pubTime":"2025-09-04 09:42","pubTimestamp":1756950165,"startTime":"0","endTime":"0","summary":"09月04日，猴痘概念盘中拉升，截至09点42分，猴痘概念整体指数上涨0.55%，报1153.320点。从个股上来看，该概念的成分股中，透景生命涨5.23%，君实生物-U、海辰药业、热景生物涨幅居前。从资金上来看，截止发稿，猴痘概念主力净流入为3989.16万，其中海辰药业受到资金热捧，主力净流入2878.01万；拉长时间线来看，该板块近20日主力资金净流入-109.60亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904094245a4b2bb8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904094245a4b2bb8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","BK1161","01877"],"gpt_icon":0},{"id":"2564431801","title":"每日卖空追踪 | 君实生物 09月03日卖空量成交4.46万股，卖空比例为0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564431801","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564431801?lang=zh_cn&edition=full","pubTime":"2025-09-03 16:30","pubTimestamp":1756888225,"startTime":"0","endTime":"0","summary":"君实生物北京时间09月03日，涨0.74%，卖空量成交4.46万股%，较上一交易日减少69.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250903172200a70d4e2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250903172200a70d4e2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2564365558","title":"东富龙：恒瑞医药、百济神州、君实生物是公司重要的合作伙伴","url":"https://stock-news.laohu8.com/highlight/detail?id=2564365558","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564365558?lang=zh_cn&edition=full","pubTime":"2025-09-03 16:19","pubTimestamp":1756887582,"startTime":"0","endTime":"0","summary":"有投资者在互动平台向东富龙提问：“公司有跟恒瑞医药，百济神州，君实生物等创新药公司合作吗？供应有哪些设备。”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/03161952894758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0012","LU1064130708.USD","BK4585","LU1997245094.SGD","600276","BK0251","BK0028","LU0405327148.USD","LU1064131003.USD","LU1997245177.USD","LU2328871848.SGD","BK1583","LU1770034418.SGD","LU2543165471.USD","BK0183","BK1161","LU0307460666.USD","BK0239","LU1255011170.USD","LU1023057109.AUD","BK4526","LU2580892862.HKD","300171","688235","BK1191","LU1997244956.HKD","LU2488822045.USD","01877","LU0359202008.SGD","BK1515","688180","LU0405327494.USD","LU1303224171.USD","LU1251922891.USD","BK0060","BK0196","LU0588546209.SGD","LU1969619763.USD","BK0188","LU0359201612.USD","06160","BK1588","BK4139","LU2495084118.USD","LU1719994722.HKD","LU1655091616.SGD","LU1328615791.USD","ONC","LU0359201885.HKD"],"gpt_icon":0},{"id":"2564689043","title":"君实生物：第四届监事会第九次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2564689043","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564689043?lang=zh_cn&edition=full","pubTime":"2025-09-03 15:37","pubTimestamp":1756885051,"startTime":"0","endTime":"0","summary":"证券日报网讯9月2日晚间，君实生物发布公告称，公司第四届监事会第九次会议审议通过了《关于及其摘要及建议向一名董事兼主要股东授予A股股票期权的议案》等多项议案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509033503527427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","01877","BK1515"],"gpt_icon":0},{"id":"2564135339","title":"君实生物激励方案发布 A+H双发力 董事长获800万份A股期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2564135339","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564135339?lang=zh_cn&edition=full","pubTime":"2025-09-03 10:20","pubTimestamp":1756866016,"startTime":"0","endTime":"0","summary":"君实生物（688180/01877）发布公告，董事会于2025年9月2日审议并批准了2025年H股和A股股票期权激励计划。计划包括向七名执行董事及三名员工授予1321万份H股股票期权，以及向董事长熊俊授予800万份A股股票期权，均须待股东于临时股东大会上批准后生效。2025年H股股票期权激励计划的授予对象包括员工参与者及关联实体参与者，激励对象资格由董事会或计划管理人确定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509033503264164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","BK1515","01877"],"gpt_icon":0},{"id":"2564638683","title":"君实生物(01877.HK)建议采纳2025年H股股票期权激励计划和2025年A股股票期权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2564638683","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564638683?lang=zh_cn&edition=full","pubTime":"2025-09-02 23:00","pubTimestamp":1756825218,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK0239","688180","159982","399300","BK1515","01877","BK1161"],"gpt_icon":0},{"id":"1183445624","title":"君实生物JT118注射液获得国家药监局临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1183445624","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183445624?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:15","pubTimestamp":1756818915,"startTime":"0","endTime":"0","summary":"君实生物JT118注射液获得国家药监局临床试验批准通知","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","688180","BK1583","BK0239","01877"],"gpt_icon":0},{"id":"2564800247","title":"君实生物(01877.HK)：JT118注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2564800247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564800247?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:12","pubTimestamp":1756818738,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK0239","688180","BK1161","BK1583","399441","01877","161726"],"gpt_icon":0},{"id":"2564016068","title":"君实生物(688180.SH)拟授出2617.59万份股票期权 行权价为46.67元/份","url":"https://stock-news.laohu8.com/highlight/detail?id=2564016068","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564016068?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:36","pubTimestamp":1756813013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(688180.SH)披露2025年A股股票期权激励计划(草案)，公司拟授予的股票期权数量为2617.5871万份(首次授予股票期权2536万份)，首次及预留授予的股票期权的行权价格为46.67元/份。首次授予股票期权的激励对象共计251人。本激励计划有效期为自股票期权首次授权之日起至激励对象获授的股票期权全部行权或注销完毕之日止，最长不超过48个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK0239","BK1161","688180","BK1583","BK1515"],"gpt_icon":0},{"id":"2564801656","title":"君实生物(688180.SH)：JT118注射液用于预防猴痘病毒感染临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801656","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564801656?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:33","pubTimestamp":1756812810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物 公告，公司控股子公司上海君拓生物医药科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，JT118注射液的临床试验申请获得批准，国家药品监督管理局同意开展用于预防猴痘病毒感染的临床试验。JT118是由猴痘病毒抗原A35和M1串联融合组成的“二合一”重组蛋白疫苗，拟主要用于预防猴痘病毒感染。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688180","BK0239","01877","BK1515","BK1583"],"gpt_icon":0},{"id":"2564547819","title":"华安证券：给予君实生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2564547819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564547819?lang=zh_cn&edition=full","pubTime":"2025-09-01 18:34","pubTimestamp":1756722887,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,任婉莹近期对君实生物进行研究并发布了研究报告《PD-1销售加速快跑，IO2.0大药稳步推进》，给予君实生物买入评级。我们看好特瑞普利单抗国内高增速，公司国际化进程，IO2.0及ADC管线推进，维持“买入”评级。 风险提示 新药研发失败、审批及准入不及预期、行业政策变化、销售浮动等最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为52.55。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100028519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180","600909"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.1136},{"period":"1month","weight":0.1996},{"period":"3month","weight":0.6159},{"period":"6month","weight":1.3248},{"period":"1year","weight":2.2243},{"period":"ytd","weight":1.9793}],"compareEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.0204},{"period":"3month","weight":0.0683},{"period":"6month","weight":0.049},{"period":"1year","weight":0.4571},{"period":"ytd","weight":0.2671}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.112475},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07747},{"month":3,"riseRate":0.714286,"avgChangeRate":0.049127},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.007532},{"month":10,"riseRate":0.333333,"avgChangeRate":0.015959},{"month":11,"riseRate":0.666667,"avgChangeRate":0.058946},{"month":12,"riseRate":0.666667,"avgChangeRate":0.125737}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}